<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03548480</url>
  </required_header>
  <id_info>
    <org_study_id>FSJD-BALPWS-2018</org_study_id>
    <nct_id>NCT03548480</nct_id>
  </id_info>
  <brief_title>Targeting the Gut Microbiome for Prader-Willi Syndrome Treatment</brief_title>
  <acronym>BALPWS</acronym>
  <official_title>Targeting the Gut Microbiome for Prader-Willi Syndrome Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundació Sant Joan de Déu</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundació Sant Joan de Déu</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The gut microbiome has recently emerged as a major contributor to obesity, systemic
      inflammation, and metabolic disease. Furthermore, intestinal bacteria are crucial players in
      the gut-brain axis, regulating a broad range of central nervous system processes, from
      satiety mechanisms to anxiety and social behavior. Thus, targeting the microbiome is being
      actively investigated as a therapeutic strategy for a wide array of diseases, including
      obesity, anxiety, depression, and autism. Among all intestinal bacteria, Bifidobacterium
      animalis spp. lactis (BAL) has shown promise for obesity treatment in experimental animal
      models and human subjects, improving body composition and metabolic health, and reducing
      energy intake. Moreover, tryptophan metabolism, a crucial regulator of satiety mechanisms and
      anxiety, is a main target of BAL. Given that clinical manifestations of Prader-Willi syndrome
      (PWS) include hyperphagia, anxiety, altered body composition, and metabolic dysregulation,
      the aforementioned effects of BAL might prove highly beneficial for children with PWS. Here,
      the investigators will test this hypothesis by performing a randomized double-blinded
      placebo-controlled crossover clinical study to assess the effects of BAL supplementation on
      an array of clinical manifestations of PWS. Children with PWS will undergo a 3-month
      placebo/probiotic treatment period, a 3-month washout period, followed by a 3-month
      probiotic/placebo supplementation. Anthropometric, biochemical, and psychological data as
      well as biological samples will be obtained at the beginning of the study, and after each of
      the study periods, with a total of four time-points. Specifically, the investigators will
      determine body composition by DXA analysis; metabolic health by assessing glucose and lipid
      metabolic parameters as well as circulating hormonal and cytokine levels; thermoregulation by
      non-invasive thermal imaging; and hyperphagia and emotional and behavioral problems by
      applying parental-rated validated questionnaires.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2018</start_date>
  <completion_date type="Actual">January 31, 2019</completion_date>
  <primary_completion_date type="Actual">January 31, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in percent body fat</measure>
    <time_frame>3 months</time_frame>
    <description>Measured by DXA scan</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in lipid profile (triglyceride, cholesterol)</measure>
    <time_frame>3 months</time_frame>
    <description>Blood test after overnight fasting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in glucose metabolic parameters (glucose, insulin, HbA1c)</measure>
    <time_frame>3 months</time_frame>
    <description>Blood test after overnight fasting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in circulating cytokine levels</measure>
    <time_frame>3 months</time_frame>
    <description>Quantified in plasma samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in hyperphagia</measure>
    <time_frame>3 months</time_frame>
    <description>Measured by validated questionnaire (HQ-CT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in thermoregulation</measure>
    <time_frame>3 months</time_frame>
    <description>Measured by thermal imaging</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in plasma metabolome</measure>
    <time_frame>3 months</time_frame>
    <description>Liquid chromatography coupled to mass spectrometry will be used to obtain a comprehensive metabolic profile of plasma samples</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in urine metabolome</measure>
    <time_frame>3 months</time_frame>
    <description>Liquid chromatography coupled to mass spectrometry will be used to obtain a comprehensive metabolic profile of urine samples</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in intestinal microbiome</measure>
    <time_frame>3 months</time_frame>
    <description>DNA isolated from fecal samples will be analyzed by sequencing.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Prader-Willi Syndrome</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Probiotic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Intervention with a daily dose of placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Probiotic</intervention_name>
    <description>Intervention with a daily dose of probiotic</description>
    <arm_group_label>Probiotic</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed with Prader-Willi Syndrome with genetic confirmation

          -  On a stable diet and medication regimen for at least the last two months before
             enrollment

        Exclusion Criteria:

          -  Current enrollment in or discontinuation within the last 30 days from a clinical trial

          -  Presence of other medical problems that would preclude study participation

          -  Patients with a history of bariatric surgery

          -  Unsuitable for inclusion in the study in the opinion of the investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>19 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carles Lerin, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fundació Sant Joan de Déu</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Sant Joan de Deu</name>
      <address>
        <city>Barcelona</city>
        <zip>08950</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>May 2, 2018</study_first_submitted>
  <study_first_submitted_qc>June 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 7, 2018</study_first_posted>
  <last_update_submitted>March 4, 2020</last_update_submitted>
  <last_update_submitted_qc>March 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prader-Willi Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

